Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 9,514 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed No phase listed Observational Accepts healthy volunteers

Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

NCT01310023
View directory record Official record
Conditions
Antiretroviral Toxicity
Interventions
Not listed
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
Not listed
Enrollment
5,169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

NCT01830920
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
THR-184, Placebo
Drug
Lead sponsor
Thrasos Innovation, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

NCT05032859
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 19, 2026, 9:10 PM EDT
Terminated No phase listed Observational

A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)

NCT03520127
View directory record Official record
Conditions
Breast Lesions
Interventions
Intact Breast Lesion Excision System (BLES)
Device
Lead sponsor
Medtronic Surgical Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Dalton, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 19, 2026, 9:10 PM EDT
Completed No phase listed Observational

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

NCT00002924
View directory record Official record
Conditions
Prostate Cancer
Interventions
mutation analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 19, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

NCT01459796
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo, Allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

NCT01072396
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 19, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Results available

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Not applicable Interventional

Acceptance and Commitment Therapy for Depressed Individuals Living With Spinal Cord Injury Sustained Within 5 Years

NCT05725161
View directory record Official record
Conditions
Depression, Spinal Cord Injuries
Interventions
Acceptance and commitment therapy (ACT), Wait-list control group with psychoeducation materials provided
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

NCT00485693
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine HCl, SKY0402
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • Davis, California • Laguna Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

NCT00329225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
130
States / cities
Birmingham, Alabama • Fairfield, Alabama • Fultondale, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Debio 1562, Rituximab
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

NCT00400634
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]), Sham Surgery
Drug · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 19, 2026, 9:10 PM EDT
Not listed Phase 2 Interventional

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

NCT00114309
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
Interventions
131-I-TM-601, 131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 19, 2026, 9:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

NCT04120493
View directory record Official record
Conditions
Huntington's Disease
Interventions
intra-striatal rAAV5-miHTT, Imitation (sham) surgery
Genetic · Other
Lead sponsor
UniQure Biopharma B.V.
Industry
Eligibility
25 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 19, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

NCT00689052
View directory record Official record
Conditions
Fibromyalgia
Interventions
pramipexole ER, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

NCT01411852
View directory record Official record
Conditions
Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions
0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

NCT01376726
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 40 mg, Lurasidone 80 mg, Placebo 40 or 80 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Not applicable Interventional Results available

Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites

NCT03340025
View directory record Official record
Conditions
Surgical Wound
Interventions
PICO Single Use Negative Pressure Wound Therapy System, xeroform gauze
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 19, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CARE Trial: Comparing Different Levels of Calorie Reduction for Weight Loss

NCT02736669
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Energy Reduction
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 19, 2026, 9:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Fiber on Insulin Sensitivity

NCT01521806
View directory record Official record
Conditions
Focus of the Study is Insulin Sensitivity
Interventions
Dietary Fiber
Dietary Supplement
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
19 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 19, 2026, 9:10 PM EDT